The heart can be protected from infarction by brief episodes of ischemia/reperfusion of a remote organ.
C ardioprotection by remote ischemic preconditioning (RIPC) is attractive 1 because it avoids manipulation of the culprit coronary artery and potential microembolization. 2 RIPC by 3 cycles of arm ischemia/reperfusion attenuated troponin release in patients undergoing coronary bypass surgery with intermittent cross-clamp fibrillation, cold blood, or crystalloid cardioplegia. [3] [4] [5] The lack of protection by RIPC in patients undergoing coronary bypass surgery in 2 recent single-center trials 6, 7 is not entirely clear but may relate to anesthesia. However, RIPC also attenuated myocardial injury in patients undergoing elective percutaneous coronary interventions 8 -10 and in patients with acute myocardial infarction during transport to the hospital 11 in the absence of anesthesia.
All forms of cardioprotection share certain elements: neurohormones and autacoids activate membrane receptors, which then initiate complex intracellular signaling cascades and ultimately converge on the mitochondria as an integration point with a decisive role for cellular survival. 12 The signaling pathways of RIPC, notably in the human heart, have not yet been addressed. We have now induced RIPC in patients undergoing elective coronary bypass surgery under isoflurane anesthesia and cold crystalloid cardioplegia 5 and obtained myocardial biopsies before ischemic cardioplegic arrest and during early reperfusion for analysis of cardioprotective signaling.
institutional Ethics Committee (No. 08 -3683). All patients gave informed consent, and the study conformed to the principles of the Declaration of Helsinki. Biopsies of 2-5 mg from the left ventricular perfusion territories undergoing revascularization were harvested before ischemic cardiac arrest and at 10 minutes reperfusion from 24 consecutive patients undergoing elective, first-time, isolated coronary bypass surgery between September 2009 and April 2011. Patients were randomly assigned on the day of surgery to receive after induction of anesthesia either an RIPC protocol (3 cycles of 5 minutes of left upper arm ischemia by inflation of a blood pressure cuff to Ն200 mm Hg and 5 minutes of reperfusion) or control (cuff left uninflated for 30 minutes). Western blot analysis was performed with antibodies against the phosphorylated and total forms of established signaling proteins (Online Tables I and II) .
Results
The 2 groups of patients did not differ in their characteristics (Online Tables III and IV ). There were no deaths within 30 days. Serial troponin I concentrations over 72 hours after surgery were reduced with RIPC ( Figure 1 ), confirming protection. The myocardial concentration of several proteins decreased during ischemia/reperfusion but not differently between groups (Online Table I ). The concentration of phosphorylated proteins did not differ between groups at baseline (Table) .
The phosphorylation of mitogen-activated protein kinases p38 and jun kinases 1 and 2/3 (JNK1, JNK2/3) increased from baseline to early reperfusion in patients with RIPC and in control patients. JNK2/3 phosphorylation during early reperfusion was less in patients with RIPC than in control patients, but such difference was not confirmed with another antibody. The phosphorylation of reperfusion injury salvage kinases, that is, protein kinase B, extracellular signal-regulated kinase 1/2, p70 ribosomal S6 protein kinase, and glycogen synthase kinase-3␤ in-creased from baseline to early reperfusion in patients with RIPC and in control patients. Also, the phosphorylation of signal transducer and activator of transcription (STAT) 3 increased from baseline to reperfusion in patients with RIPC and in control patients. STAT1 phosphorylation increased significantly from baseline to early reperfusion only in control patients, but there was no significant difference between patients with RIPC and control patients during early reperfusion. In contrast, STAT5 phosphorylation increased from baseline to early reperfusion only in patients with RIPC and not in control patients. This increment was confirmed with 2 different antibodies, and there was a significant difference between patients with RIPC and control patients during early reperfusion, again confirmed by 2 different antibodies ( Figure 2 ).
Discussion
Only STAT5 activation was associated with protection by RIPC in the present study. Increased STAT5 phosphorylation has been reported in human ischemic cardiomyopathy before but was not related to function or protection. 13 The role of STAT5 in the protection of experimental animals is controversial. A causal role for infarct size reduction by ischemic preconditioning was attributed to STAT5a in isolated rat and mouse hearts. 14 In another study using mice, STAT5 phosphorylation was increased by preconditioning in wild types and even more so in STAT3 knockouts but could not compensate for loss of STAT3 and provide functional protection. 15 Increased ischemic creatine kinase release along with STAT5 activation resulted in mice with overexpression of human aldose reductase. 16 Conversely, attenuated rather than increased STAT5 phosphorylation during reperfusion was associated with smaller infarct size. 17 Also, in rats with coronary ligation, cardioprotection by vitamin C was associated with inhibition of STAT5b phosphorylation. 18 From the available data, it appears that the function of STAT3 and STAT5 might have reverse functions in animals and humans: STAT5 but not STAT3 activation is associated with protection in human hearts, whereas STAT3 activation 19 and possibly STAT5 inhibition are associated with protection in animals. Alternatively, different procedures and protocols of cardioprotection may recruit a different pattern of STAT isoform signaling.
Our patient cohort is small and currently restricted to nondiabetic patients. Proof for a causal role of STAT5 would require STAT5 inhibition, but this appears currently impossible in humans. The cellular compartment of STAT5 activation remains to be identified; a contribution of STAT5 to stem cell renewal has been reported, 20 and stem cells may contribute to more long-term protection by RIPC. Also, we do not know which cardioprotective function results from enhanced STAT5 phosphorylation; enhanced STAT3 phosphorylation is associated with improved mitochondrial function in ischemic/reperfused myocardium. 19 The recognition of STAT5 activation as a signaling event opens a new avenue for pharmacological recruitment of cardioprotection. With a better understand- RIPC indicates remote ischemic preconditioning; AKT, protein kinase B; eNOS, endothelial nitric oxide synthase; ERK, extracellular signal-regulated kinase; GSK3␤, glycogen synthase kinase-3␤; H11/HSP22, H11 kinase/heat shock protein 22; JAK, Janus kinase; JNK, jun kinase mitogen-activated kinase; p38 MAPK, p38 mitogen-activated protein kinase; p70S6K, p70 ribosomal S6 protein kinase; PKC, protein kinase C; ser, serine; Src, Src protein tyrosine kinase; STAT, signal transducer and activator of transcription; thr, threonine; tyr, tyrosine; and VASP, vasodilator-stimulated phosphoprotein. PKC and H11/HSP22 are only assessed as total protein. Note that baseline and reperfusion data differ between the upper and lower parts of the table because they are derived from separate gels, and statistical comparisons are made only for data from the same gel.
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ing of upstream and downstream events of STAT5 activation, we can then extend our studies to larger patient cohorts with various comorbidities and a greater perioperative risk.
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